LACTOLOGY FOUNDATION

Clebopride (ATC A03FA06) is a dopamine‑antagonist prokinetic antiemetic used for functional gastrointestinal disorders, with clinically relevant safety concerns and very limited lactation data.medpedia.framar+6

Monograph overview

Clebopride is a substituted benzamide derivative classified under ATC A03FA06 “propulsives,” indicating its role as a prokinetic agent that enhances gastrointestinal motility and exerts antiemetic effects. It is marketed mainly as clebopride malate in oral solid forms such as tablets and hard capsules, often indicated for nausea, vomiting and symptoms of functional dyspepsia or other functional gastrointestinal disorders. As a centrally acting dopamine D₂ antagonist with additional serotonergic activity, clebopride shares pharmacodynamic characteristics with other benzamide prokinetics (e.g. metoclopramide, cisapride‑like agents), but with its own adverse‑effect profile.bbfarma+6

Pharmacology and mechanism of action

Clebopride acts primarily as a dopamine D₂‑receptor antagonist in the chemoreceptor trigger zone and within the enteric nervous system, thereby reducing nausea and vomiting and enhancing coordinated gastric and intestinal motility. Experimental data suggest that clebopride malate also behaves as a partial agonist at serotonin 5‑HT₄ receptors, which further facilitates acetylcholine release in the myenteric plexus and promotes peristaltic activity. This dual dopaminergic and serotonergic modulation accounts for both its gastroprokinetic and antiemetic actions, leading to improved gastric emptying and symptomatic relief in functional gastrointestinal disorders.wikipedia+3

Indications and clinical use

Clinically, clebopride is indicated for the treatment of nausea and vomiting of various etiologies, including those associated with functional gastrointestinal disorders and, in some studies, with emetogenic chemotherapy such as cisplatin. In addition, it is used to relieve upper gastrointestinal symptoms such as epigastric discomfort, early satiety and postprandial fullness when these are attributed to motility disturbances rather than structural disease. Its place in therapy is often as a short‑term prokinetic antiemetic; however, concerns about extrapyramidal and movement‑disorder adverse effects have limited enthusiasm for long‑term or high‑dose use.drugbank+5

Dosage and administration

Clebopride is administered orally, commonly in tablet or hard capsule form containing clebopride malate alone or in fixed combination with simethicone for additional antiflatulent effect. Standard adult oral doses described in product information and trials typically involve multiple daily administrations (e.g. three times daily), adjusted to symptom intensity and patient tolerance, with doses above these ranges avoided due to dose‑related extrapyramidal toxicity observed in phase I studies. As with other centrally acting antidopaminergic prokinetics, dose individualisation is recommended, considering age, comorbidities and concurrent dopaminergic or serotonergic agents.atcddd.fhi+4

Contraindications and precautions

Clebopride is contraindicated in patients with known hypersensitivity to the active substance or excipients and should be avoided in individuals with a history of drug‑induced extrapyramidal reactions to dopamine antagonists. Additional precautions are warranted in patients with Parkinson’s disease or other baseline movement disorders, given the potential for symptom exacerbation through central D₂ blockade. Trials and clinical protocols frequently list pregnancy and breastfeeding among exclusion criteria, reflecting the absence of firm safety data rather than documented high risk, and suggest caution in systemic diseases affecting oesophageal motility or psychiatric conditions in which dopamine antagonism could be problematic.clinicaltrials+3

Adverse effects and toxicological profile

Common adverse reactions to clebopride include somnolence, fatigue, diarrhoea and cutaneous allergic manifestations such as rash. A key toxicological concern is the development of extrapyramidal‑like symptoms (e.g. acute dystonia, akathisia, parkinsonism), which have been noted at various dose levels in phase I oncology trials and can limit continuation of therapy. More recent clinical observations have described an unusually high number of clebopride‑associated movement disorders, underlining its risk profile as a centrally acting dopamine antagonist and supporting recommendations for cautious, short‑term use and careful monitoring.pubmed.ncbi.nlm.nih+2

Lactation safety and transfer into breast milk

Specific human data on clebopride excretion into breast milk and on breastfed infant exposure are currently lacking, and clebopride is often excluded from lactation safety reviews, indicating that it is not a well‑studied agent in breastfeeding populations. General principles of lactational pharmacology suggest that a relatively high molecular weight and oral administration may limit direct transfer and reduce infant oral bioavailability, but dopamine antagonists as a class can affect central neurotransmission and may theoretically influence neonatal motor function or prolactin‑related physiology. In the absence of dedicated studies, expert documents dealing with drug safety in breastfeeding women tend to recommend preference for agents with documented lactation profiles, reserving poorly studied drugs such as clebopride for situations where no safer, better‑characterised alternative is available.pmc.ncbi.nlm.nih+3

Practical toxicological‑lactological assessment

From a practical standpoint, clebopride combines beneficial prokinetic and antiemetic actions with non‑trivial central dopaminergic toxicity and an evidence gap in breastfeeding, placing it in a cautious‑use bracket for lactating patients. When symptom control in the mother is essential and alternative prokinetics or antiemetics with established lactation safety are unavailable or ineffective, short‑term, lowest‑effective‑dose use may be considered under close clinical supervision, with careful monitoring of the infant for sedation, feeding difficulties, abnormal movements or irritability. In routine practice, however, many clinicians will prefer better‑studied agents, especially when treating benign functional gastrointestinal complaints in breastfeeding women.pmc.ncbi.nlm.nih+4

Placement in our innovative toxicological‑lactological categories

Within our innovative toxicological‑lactological classification framework, which we propose to colleagues worldwide as more adaptive to everyday practice and more ultimative as guidance for practical drug selection, clebopride (A03FA06) is assigned to a category reflecting “centrally acting dopamine‑antagonist prokinetics with limited lactation data and documented extrapyramidal risk.” This category highlights the dual reality for clinicians: meaningful symptomatic benefit at the gastrointestinal level, contrasted with central nervous system toxicity and an absence of robust breastfeeding pharmacokinetic and safety studies, thus calling for a risk–benefit analysis tailored to each mother–infant pair. By formalising such nuanced categories, our toxicological‑lactological system aims to provide a more practice‑oriented and decision‑supportive structure than traditional, purely regulatory or ATC‑based classifications, facilitating clearer communication and more consistent choices in lactation pharmacotherapy.synapse.patsnap+7